Table 5.
Clinical Characteristics of Children and Adolescents With Lymphoma Categorized by Disease.
| Overall (n = 114) | Burkitt (n = 74) | DLBCL (n = 6) | LBL (n = 13) | Hodgkin (n = 21) | P Value | |
|---|---|---|---|---|---|---|
| Median age in years (range) | 8.4 (2.1-16.3) | 7.6 (2.2-16.3) | 11 (2.1-14.1) | 9 (4-12.8) | 11.5 (3.3-15.3) | .03 |
| Female gender, n (%) | 41 (36%) | 27 (36%) | 2 (33%) | 6 (46%) | 6 (29%) | .78 |
| Clinical presentation, n (%) | ||||||
| Abdominal mass | 58 (51%) | 40 (54%) | 4 (67%) | 8 (62%) | 6 (29%) | .13 |
| Peripheral LAD | 40 (35%) | 7 (9%) | 4 (67%) | 9 (69%) | 20 (95%) | <.01 |
| Jaw mass | 39 (34%) | 39 (53%) | 0 | 0 | 0 | <.01 |
| CNS involvement | 18 (16%) | 16 (22%) | 1 (17%) | 1 (8%) | 0 | .06 |
| Periorbital mass | 15 (13%) | 14 (19%) | 1 (17%) | 0 | 0 | .04 |
| Mediastinal mass | 13 (11%) | 0 | 0 | 10 (77%) | 3 (14%) | <.01 |
| Cytopenias | 11 (10%) | 4 (5%) | 1 (17%) | 4 (31%) | 2 (10%) | .02 |
| Pathology confirmation, n (%) | 47 (41%) | 17 (23%) | 5 (83%) | 7 (54%) | 18 (86%) | <.01 |
| HIV infected, n (%) | 4 (4%) | 3 (4%) | 0 | 0 | 1 (5%) | 1.00 |
| Clinical staging, n (%) | —a | |||||
| Stage I/II | 37 (32%) | 25 (34%) | 1 (17%) | 0 | 11 (52%) | |
| Stage III | 46 (40%) | 29 (39%) | 3 (50%) | 8 (62%) | 6 (29%) | .03 |
| Stage IV | 30 (26%) | 20 (27%) | 2 (33%) | 5 (38%) | 3 (14%) | |
| Median symptom duration, months (range) | 2 (0.5-36) | 1.5 (0.5-4) | 2.5 (1.5-3.5) | 2 (1-4) | 9 (3-36) | <.01 |
| Overall survival | ||||||
| 12-Month (95% CI) | 36% (27-46) | 38% (27-49) | 15% (2-39) | 46% (24-65) | .2 | |
| 18-Month (95% CI) | 29% (20-38) | 33% (22-44) | 0 | 38% (17-59) | ||
| Median survivor follow-up, months (range) | 16 (3-31) | 18 (3-31) | N/A | 13 (5-26) | ||
| Treatment abandonment, n (%) | 18 (16%) | 13 (16%) | 1 (8%) | 4 (19%) | .72 | |
| Number of deaths, n (%) | 57 (50%) | 36 (45%) | 12 (92%) | 10 (48%) | .03 | |
| Deaths from disease | 46 (40%) | 28 (35%) | 12 (92%) | 7 (33%) | .01 | |
| Treatment-related deaths | 7 (6%) | 6 (8%) | 0 | 1 (5%) | .91 | |
| Deaths in complete remission | 4 (4%) | 2 (3%) | 0 | 2 (10%) | .22 | |
| Median time to death, months (range) | 7 (0.1-26) | 5.5 (0.1-26) | 9 (1-17) | 9 (0.1-23) | .51 | |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; LBL, lymphoblastic lymphoma; LAD, lymphadenopathy; CNS, central nervous system; HIV, human immunodeficiency virus.
a
One patient with Hodgkin lymphoma abandoned treatment prior to staging, and 8 of 11 stage I/II patients were stage II with bulky disease. Note that for outcome results, Burkitt and DLBCL patients were analyzed as a combined group of patients with mature B-cell non-Hodgkin lymphoma.